|

Serum Vasohibin, Cardiotrophin, Endocan & Perinatal Outcomes

RECRUITINGSponsored by Umraniye Education and Research Hospital
Actively Recruiting
SponsorUmraniye Education and Research Hospital
Started2023-03-03
Est. completion2024-11-30
Eligibility
Age18 Years – 39 Years
SexFEMALE
View on ClinicalTrials.gov →

NCT06416995

Summary

Investigation of the relationship between maternal serum vasohibin-1, vasohibin-2, cardiotrophin -1 and endocan concentrations at the 11th and 14th weeks of gestation and adverse perinatal outcomes.

Eligibility

Age: 18 Years – 39 YearsSex: FEMALE
Inclusion Criteria:

* Those who had the first-trimester screening test between 11 and 14 weeks of pregnancy and are in the low-risk group
* Those with singleton pregnancy
* Those who did not conceive pregnancy with assisted reproductive treatment methods
* Those who do not have any pregestational diseases
* Those who do not have any uterine anomalies

Exclusion Criteria:

* Smokers
* Those who are in the high-risk group with the first trimester screening test
* Those with multiple pregnancies
* Those who conceive with assisted reproductive treatment methods
* Those who had any disease before pregnancy
* Those who have any uterine anomalies

Conditions6

DiabetesFetal Growth RetardationGestational DiabetesGestational HypertensionPreeclampsiaPreterm Birth

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.